Even though lung and related cancer deaths decreased in the world's 10 most populous countries from 1990 to 2019, these ...

For patients with advanced or recurrent endometrial cancer, first-line Lenvima plus Keytruda didn’t significantly improve ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the ...

TrialTranslator uses machine learning to assess cancer RCT generalizability, revealing survival gaps for high-risk patients ...

Romania's Sibiu County Emergency Clinical Hospital will receive a robotic system to prepare cytostatic drugs needed by cancer ...

Boehringer Ingelheim announced a partnership with Synaffix to advance antibody-drug conjugates and exercised its fourth ...

Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 ...

Zymeworks (NYSE: ZYME) came into focus in late December when major shareholder EcoR1 Capital increased its stake. Already a ...

IGM Biosciences Inc. said Thursday it is cutting 73% of its workforce after deciding to halt further development of a program relating to its autoimmunity-drug pipeline, sending its stock down 69% in ...

Top stocks for 2025 are from the companies that have proven growth track records and strong outlooks, with more potential ...

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...

Chicago-based Meitheal Pharmaceuticals, along with its Chinese parent, was busy in 2024, adding both biosimilar drugs and ...